Search results
Results from the WOW.Com Content Network
By Eva Mathews (Reuters) -Haleon plans to buy back 500 million pounds ($633 million) of its shares this year amid firm demand for its products and progress in reducing debt, sending the British ...
Pfizer, which currently holds a 32% stake in Haleon, said last year it planned to cut its ownership in a "slow and methodical" manner within months. The offer price per share is expected to be ...
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir Dave Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in ...
Haleon said half-year organic revenue grew 5.6% in its "power brands", with toothpaste products Sensodyne and Parodontax along with multi-vitamin product Centrum achieving double-digit growth.
About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS).
(Reuters) -Haleon plans to increase its stake in its Chinese joint venture to 88% from 55%, the British consumer healthcare company said on Friday. It will pay 4.47 billion yuan ($637 million) to ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.